Research
Metabolic adaptation
Dapagliflozin treatment is associated with weight reduction and a low propensity to cause hypoglycemia.
Dapagliflozin may help patients lose weight while minimizing the risk of low blood sugar.
StrongSupportsmedium confidence
Dapagliflozin treatment is associated with weight reduction, it has a low intrinsic propensity to cause hypoglycemia.
Why this rating
The claim is supported by clinical trial findings.
Source
Dapagliflozin: A new sodium–glucose cotransporter 2 inhibitor for treatment of type 2 diabetes
Eva Vivian · American Journal of Health-System Pharmacy · 2015
reviewCited 44×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →